Current debate on pathogen inactivation of platelet concentrates - To use or not to use?

Transfusion and Apheresis Science

Volumn 43, Issue 3, 2010, Pages 411-414

  Hervig, Tor ^a,b   Seghatchian, Jerard ^c   Apelseth, Torunn Oveland ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c Blood Components Technology Consultancy   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; PSORALEN; THROMBOCYTE CONCENTRATE;

ARTICLE; AVIAN INFLUENZA VIRUS; BACTERIAL GROWTH; BACTERIAL TRANSMISSION; BACTERIUM CONTAMINATION; BLOOD DONOR; BLOOD TRANSFUSION REACTION; CHIKUNGUNYA ALPHAVIRUS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; GAMMA IRRADIATION; HEPATITIS B; HEPATITIS C; HLA MATCHING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; RISK REDUCTION; SWINE INFLUENZA VIRUS; THROMBOCYTE TRANSFUSION; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; WEST NILE FLAVIVIRUS;

BLOOD PLATELETS; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; DISINFECTION; HUMANS; PLATELET TRANSFUSION;

EID: 78649467309     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2010.10.012     Document Type: Article

References (38)

1. Webert K.E., Cserti C.M., Hannon J., et al. Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008, 22:1-34.
2. Roback J.D., Conlan M., Drew W.L., et al. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections. Transfus Med Rev 2006, 20:45-56.
3. O'Brien S.F., Yi Q.L., Fan W., et al. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007, 47:316-325.
4. Blajchman M.A., Goldman M., Baeza F. Improving the bacteriological safety of platelet transfusions. Transfus Med Rev 2004, 18:11-24.
5. Blajchman M.A., Goldman M. Bacterial contamination of platelet concentrates: incidence, significance, and prevention. Semin Hematol 2001, 38:20-26.
6. Benjamin R.J., Wagner S.J. The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two-bottle culture systems and an estimation of false-negative culture rates. Transfusion 2007, 47:1381-1389.
7. Schrezenmeier H., Walther-Wenke G., Muller T.H., et al. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007, 47:644-652.
8. Dreier J., Stormer M., Pichl L., et al. Sterility screening of platelet concentrates: questioning the optimal test strategy. Vox Sang 2008, 95:181-188.
9. Hillyer C.D., Josephson C.D., Blajchman M.A., et al. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematol Am Soc Hematol Educ Program 2003, 575-589.
10. Yazer M.H., Stapor D., Triulzi D.J. Use of the RQI test for bacterial screening of whole blood platelets. Am J Clin Pathol 2010, 133:564-568.
11. Dodd R. Managing the microbiological safety of blood for transfusion: a US perspective. Future Microbiol 2009, 4:807-818.
12. Rasongles P., Angelini-Tibert M.F., Simon P., et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Reunion. Transfusion 2009, 49:1083-1091.
13. Osselaer J.C., Messe N., Hervig T., et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008, 48:1061-1071.
14. Marschner S, Fast LD, Baldwin Iii WM, et al. White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010 [Epub ahead of print].
15. Mintz P.D., Wehrli G. Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products. Bone Marrow Transplant 2009, 44:205-211.
16. Ciaravino V., Hanover J., Lin L., et al. Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats. Transfusion 2009, 49:985-994.
17. Reddy H.L., Dayan A.D., Cavagnaro J., et al. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008, 22:133-153.
18. Ciaravi V., McCullough T., Dayan A.D. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol 2001, 20:533-550.
19. Apelseth T.O., Bruserud O., Wentzel-Larsen T., et al. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion 2007, 47:653-665.
20. Apelseth T.O., Hervig T. In vitro evaluation of platelet concentrates during storage: platelet counts and markers of platelet destruction. Transf Apheres Sci 2007, 37:261-268.
21. Apelseth T.O., Hervig T.A., Wentzel-Larsen T., Bruserud O. Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion 2006, 46:800-810.
22. Picker S.M., Oustianskaia L., Schneider V., Gathof B.S. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang 2009, 97:26-33.
23. Picker S.M., Schneider V., Gathof B.S. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies. Transfusion 2009, 49:1224-1232.
24. Picker S.M., Schneider V., Oustianskaia L., Gathof B.S. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009, 49:2311-2318.
25. Picker S.M., Speer R., Gathof B.S. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004, 44:320-329.
26. Seghatchian J., de Sousa G. Pathogen-reduction systems for blood components: the current position and future trends. Transf Apheres Sci 2006, 35:189-196.
27. Solheim B.G., Seghatchian J. Pathogen reduction of blood components. Transf Apheres Sci 2008, 39:75-82.
28. van Rhenen D., Gulliksson H., Cazenave J.P., et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003, 101:2426-2433.
29. Snyder E., McCullough J., Slichter S.J., et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005, 45:1864-1875.
30. Simonsen A.C., Johansson P.I., Conlan M.G., et al. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 2006, 46:424-433.
31. Apelseth T.O., Bruserud O., Wentzel-Larsen T., Hervig T. Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods. Transfusion 2009, 50:766-775.
32. Kerkhoffs J.L., van Putten W.L., Novotny V.M., et al. Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010, 150:209-217.
33. Bell C.E., Botteman M.F., Gao X., et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther 2003, 25:2464-2486.
34. Janssen M.P., van der Poel C.L., Buskens E., et al. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006, 46:956-965.
35. Moeremans K., Warie H., Annemans L. Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med 2006, 16:17-30.
36. Postma M.J., van Hulst M., De Wolf J.T., et al. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med 2005, 15:379-387.
37. Staginnus U., Corash L. Economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematol 2004, 80:317-324.
38. Knutson F.L.K., Løf H. A feasibility study with the Tasci device producing 2 doses of platelets stored for 7days with the use of one Intercept pathogen inactivation kit. Vox Sang 2010, 99:202.